The new funds will help drive Us2.ai's growth targets for clinical implementation of its Us2.v1 echocardiography image analysis software in the U.S., Europe, and Asia, as well as expand commercial activities with pharmaceutical companies, research labs, and imaging providers worldwide, the company said.

The software, which was cleared by the U.S. Food and Drug Administration in September 2021, automatically processes full echocardiographic studies of 2D and Doppler images from any vendor in less than two minutes, delivering complete echo reports, with measurements, editable annotations, and conclusions for every chamber of the heart, Us2.ai said.

The round was led by IHH Healthcare and Heal Partners, with participation from Pappas Capital and existing investors including Sequoia India, EDBI, and Partech Ventures.